Cargando…

High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome

Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and/or morbid pregnancy, accompanied by persistent antiphospholipid antibody (aPL) positivity. However, due to the complex pathogenesis of APS and the large individual differences in the expression of aPL profiles of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qi, Yang, Shuo, Tan, Yuan, Cui, Liyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235516/
https://www.ncbi.nlm.nih.gov/pubmed/37275905
http://dx.doi.org/10.3389/fimmu.2023.1128245
_version_ 1785052696565252096
author Liu, Qi
Yang, Shuo
Tan, Yuan
Cui, Liyan
author_facet Liu, Qi
Yang, Shuo
Tan, Yuan
Cui, Liyan
author_sort Liu, Qi
collection PubMed
description Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and/or morbid pregnancy, accompanied by persistent antiphospholipid antibody (aPL) positivity. However, due to the complex pathogenesis of APS and the large individual differences in the expression of aPL profiles of patients, the problem of APS diagnosis, prognosis judgment, and risk assessment may not be solved only from the antibody level. It is necessary to use new technologies and multiple dimensions to explore novel APS biomarkers. The application of next-generation sequencing (NGS) technology in diseases with a high incidence of somatic mutations, such as genetic diseases and tumors, has been very mature. Thus, we try to know the research and application progress of APS by NGS technology from genome, transcriptome, epigenome and other aspects. This review will describe the related research of NGS technology in APS and provide more reference for the deep understanding of APS-related screening markers and disease pathogenesis.
format Online
Article
Text
id pubmed-10235516
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102355162023-06-03 High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome Liu, Qi Yang, Shuo Tan, Yuan Cui, Liyan Front Immunol Immunology Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and/or morbid pregnancy, accompanied by persistent antiphospholipid antibody (aPL) positivity. However, due to the complex pathogenesis of APS and the large individual differences in the expression of aPL profiles of patients, the problem of APS diagnosis, prognosis judgment, and risk assessment may not be solved only from the antibody level. It is necessary to use new technologies and multiple dimensions to explore novel APS biomarkers. The application of next-generation sequencing (NGS) technology in diseases with a high incidence of somatic mutations, such as genetic diseases and tumors, has been very mature. Thus, we try to know the research and application progress of APS by NGS technology from genome, transcriptome, epigenome and other aspects. This review will describe the related research of NGS technology in APS and provide more reference for the deep understanding of APS-related screening markers and disease pathogenesis. Frontiers Media S.A. 2023-05-19 /pmc/articles/PMC10235516/ /pubmed/37275905 http://dx.doi.org/10.3389/fimmu.2023.1128245 Text en Copyright © 2023 Liu, Yang, Tan and Cui https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Liu, Qi
Yang, Shuo
Tan, Yuan
Cui, Liyan
High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome
title High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome
title_full High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome
title_fullStr High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome
title_full_unstemmed High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome
title_short High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome
title_sort high-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235516/
https://www.ncbi.nlm.nih.gov/pubmed/37275905
http://dx.doi.org/10.3389/fimmu.2023.1128245
work_keys_str_mv AT liuqi highthroughputsequencingtechnologyfacilitatesthediscoveryofnovelbiomarkersforantiphospholipidsyndrome
AT yangshuo highthroughputsequencingtechnologyfacilitatesthediscoveryofnovelbiomarkersforantiphospholipidsyndrome
AT tanyuan highthroughputsequencingtechnologyfacilitatesthediscoveryofnovelbiomarkersforantiphospholipidsyndrome
AT cuiliyan highthroughputsequencingtechnologyfacilitatesthediscoveryofnovelbiomarkersforantiphospholipidsyndrome